High-dose topical bevacizumab for corneal neovascularization

Area of Science:

• Ophthalmology
• Vascular Biology
• Regenerative Medicine

Background:

• Bevacizumab (Avastin) is an anti-vascular endothelial growth factor (VEGF) agent.
• Intravitreal bevacizumab is established for ocular pathologies.
• Off-label topical use for corneal neovascularization requires investigation.

Purpose of the Study:

• To evaluate the efficacy of high-dose topical bevacizumab.
• To assess its safety profile in treating corneal neovascularization.

Main Methods:

• Seventeen eyes with corneal neovascularization were treated with topical bevacizumab (25 mg/ml) four times daily for two weeks.
• Evaluated parameters included visual acuity, slit-lamp examination, intraocular pressure, heart rate, and blood pressure.
• Color photography documented changes at baseline and day 14.

Main Results:

• Corneal neovascularization regression and/or corneal opacification clearing occurred in 11 eyes (65%).
• Adverse ocular events were mild and transient, including eyelid swelling and superficial punctate keratitis.
• No significant systemic effects on blood pressure or heart rate were noted.

Conclusions:

• High-dose topical bevacizumab (25 mg/ml) demonstrated significant efficacy in treating corneal neovascularization.
• The treatment was well-tolerated, with mild and transient adverse ocular effects.
• Topical bevacizumab presents a potentially effective and safe therapeutic option for corneal neovascularization.